The Biden Administration recently announced that it would allow the COVID-19 public health emergency (“PHE”) to expire on May 11, 2023. Coming more than three years after the Secretary of the U.S. Department of Health and Human Services (“HHS”) declared the PHE, the decision not to renew the emergency declaration will directly affect multiple stakeholders in the health care system, including life sciences companies.